blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1392676

EP1392676 - HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.10.2007
Database last updated on 02.11.2024
Most recent event   Tooltip13.03.2020Change - lapse in a contracting state
State(s) deleted from list of lapses: TR
published on 15.04.2020  [2020/16]
Applicant(s)For all designated states
Aventis Pharmaceuticals Inc.
300 Somerset Corporate Boulevard
Bridgewater, NJ 08807 / US
[N/P]
Former [2006/47]For all designated states
AVENTIS PHARMACEUTICALS INC.
300 Somerset Corporate Boulevard
Bridgewater, NJ 08807 / US
Former [2006/44]For all designated states
Aventis Pharmaceuticals, Inc.
300 Somerset Corporate Boulevard
Bridgewater, New Jersey 08807 / US
Former [2004/10]For all designated states
Aventis Pharmaceuticals, Inc.
300 Somerset Corporate Boulevard
Bridgwater, New Jersey 08807-2854 / US
Inventor(s)01 / HENDRIX, James, A.
4 Aspen Drive
Hillsborough, NJ 08876 / US
02 / STRUPCZEWSKI, Joseph, T.
4 Stewart Lane
Flemington, NJ 08822 / US
03 / BORDEAU, Kenneth, J.
211 Durham-Nox Road
Kintnersville, PA 18930 / US
04 / BROOKS, Sarah
276 Massachusetts Avenue, Apt. 104
Arlington, MA 02174 / US
05 / HEMMERLE, Horst
Oranienstrasse 11a
D-65812 Bad Soden / DE
06 / URMANN, Matthias
Im Sylvaner 4b
D-65760 Eschborn / DE
07 / ZHAO, Xu-Yang
7 Decker Lane
Bridgewater, NJ 08807 / US
08 / MUELLER, Paul, Justin.
1300 Clinton Street, Apt. 326
Hoboken, NJ 07030 / US
 [2004/10]
Representative(s)Fischer, Hans-Jürgen, et al
Sanofi-Aventis Deutschland GmbH
Patent- und Lizenzabteilung
Industriepark Höchst
Gebaüde K 801
65926 Frankfurt am Main / DE
[N/P]
Former [2004/10]Fischer, Hans-Jürgen, et al
Aventis Pharma Deutschland GmbH, Patent- und Lizenzabteilung, Gebäude K 801
65926 Frankfurt am Main / DE
Application number, filing date02714914.515.02.2002
[2004/10]
WO2002US04560
Priority number, dateUS20010269654P16.02.2001         Original published format: US 269654 P
GB2001001795023.07.2001         Original published format: GB 0117950
[2004/10]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO02066468
Date:29.08.2002
Language:EN
[2002/35]
Type: A2 Application without search report 
No.:EP1392676
Date:03.03.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 29.08.2002 takes the place of the publication of the European patent application.
[2004/10]
Type: B1 Patent specification 
No.:EP1392676
Date:13.12.2006
Language:EN
[2006/50]
Search report(s)International search report - published on:EP17.10.2002
ClassificationIPC:C07D333/62, C07D333/54, C07D498/04, C07D495/04, A61K31/381, A61P25/18
[2004/10]
CPC:
C07D231/12 (EP); A61P13/12 (EP); A61P25/00 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/22 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P43/00 (EP);
C07D233/56 (EP); C07D249/08 (EP); C07D333/66 (EP);
C07D451/02 (EP); C07D495/04 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2004/10]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:HETEROCYCLISCHE HARNSTOFFDERIVATE UND DEREN VERWENDUNG ALS DOPAMINE D3 RECEPTOR LIGANDEN[2004/10]
English:HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS[2004/10]
French:NOUVEAUX DERIVES D'UREE HETEROCYCLIQUES ET LEUR UTILISATION EN TANT QUE LIGANDS DES RECEPTEURS DE LA DOPAMINE D3[2004/10]
Entry into regional phase16.09.2003National basic fee paid 
16.09.2003Designation fee(s) paid 
16.09.2003Examination fee paid 
Examination procedure16.09.2002Request for preliminary examination filed
International Preliminary Examining Authority: EP
16.09.2003Examination requested  [2004/10]
08.03.2004Despatch of a communication from the examining division (Time limit: M06)
20.09.2004Reply to a communication from the examining division
11.01.2006Despatch of a communication from the examining division (Time limit: M04)
11.05.2006Reply to a communication from the examining division
12.06.2006Communication of intention to grant the patent
23.10.2006Fee for grant paid
23.10.2006Fee for publishing/printing paid
Opposition(s)14.09.2007No opposition filed within time limit [2007/47]
Fees paidRenewal fee
01.03.2004Renewal fee patent year 03
28.02.2005Renewal fee patent year 04
28.02.2006Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY13.12.2006
LU15.02.2007
MC28.02.2007
[2020/16]
Former [2015/21]CY13.12.2006
LU15.02.2007
TR15.02.2007
MC28.02.2007
Former [2013/10]CY13.12.2006
LU15.02.2007
MC28.02.2007
Former [2009/42]CY13.12.2006
TR13.12.2006
LU15.02.2007
MC28.02.2007
Former [2009/38]CY13.12.2006
LU15.02.2007
MC28.02.2007
Former [2007/48]MC28.02.2007
Cited inInternational search[Y]EP0395313  (AMERICAN HOME PROD [US], et al) [Y] 1-47 * examples 1,2; claim - *;
 [A]US5393761  (PERREGAARD JENS K [DK], et al) [A] 1-47 * column 7, line 66 - column 8, line 20; examples 13,15; claim 1 *;
 [A]US5990114  (LEONARDI AMEDEO [IT], et al) [A] 1-47 * column 15, line 57 - line 58; claim 1 * * column 16, line 1 - line 5 *;
 [DA]WO0067847  (BASF AG [DE], et al) [DA] 1-47 * page 3, line 1 - page 6, line 20; examples 1,2,12 *;
 [Y]  - ISHIZUMI K ET AL, "Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds.", MEDLINE, (199512), Database accession no. NLM8582016, XP002204864 [Y] 1-47 * abstract *
    [ ] - CROSSFIRE BEILSTEIN, BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT AM MAIN, DE, XP002204865 [ ] * abstract *
    [ ] - ISHIZUMI K ET AL, "Succinimide derivatives. II. Synthesis and antipsychotic activity of N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)1,2-cis-cyclohexanedicarboximide (SM-9018) and related compounds", CHEMICAL & PHARMACEUTICAL BULLETIN, JAPAN DEC 1995, (199512), vol. 43, no. 12, pages 2139 - 2151
 [A]  - MURRAY P J ET AL, "A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, (19950202), vol. 5, no. 3, ISSN 0960-894X, pages 219 - 222, XP004135762 [A] 1-47 * page 220; table 1 *

DOI:   http://dx.doi.org/10.1016/0960-894X(95)00011-H
 [Y]  - SOKOLOFF P ET AL, "MOLECULAR CLONING AND CHARACTERIZATION OF A NOVEL DOPAMINE RECEPTOR(D3) AS A TARGET FOR NEUROLEPTICS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, (19900913), vol. 347, ISSN 0028-0836, pages 146 - 151, XP000652293 [Y] 1-47 * page 150, column R, paragraph 2 *

DOI:   http://dx.doi.org/10.1038/347146a0
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.